H.R. 5160 · 119th Congress (2025–2027)
Stem Cell Therapeutic and Research Reauthorization Act of 2025
This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA).
The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research.
Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.
Show official title
To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.
Passed House
This bill’s path
319 days after it was introduced
This is H.R. 5160’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced10 months
Passed House
Passed Senate
Sent to President
Signed into law
- Sponsor
- Rep. Christopher H. Smith (R-NJ-4)
- Cosponsors
21 cosponsors
5 original · 16 later
10 R · 11 D
- Rep. Gus M. Bilirakis (R-FL-12)· Original · Sep 4, 2025
- Rep. Kweisi Mfume (D-MD-7)· Original · Sep 4, 2025
- Rep. Doris O. Matsui (D-CA-7)· Original · Sep 4, 2025
- Rep. Chellie Pingree (D-ME-1)· Original · Sep 4, 2025
- Rep. Claudia Tenney (R-NY-24)· Original · Sep 4, 2025
- Rep. Debbie Dingell (D-MI-6)· Later · Feb 4, 2026
- Rep. Michelle Fischbach (R-MN-7)· Later · Feb 4, 2026
- Rep. Robert B. Aderholt (R-AL-4)· Later · Feb 10, 2026
- Rep. Josh Gottheimer (D-NJ-5)· Later · Feb 10, 2026
- Rep. Kathy Castor (D-FL-14)· Later · Apr 2, 2026
- Rep. Andrew R. Garbarino (R-NY-2)· Later · Apr 2, 2026
- Rep. Nicole Malliotakis (R-NY-11)· Later · Apr 2, 2026
- Del. Eleanor Holmes Norton (D-DC)· Later · Apr 2, 2026
- Rep. Cliff Bentz (R-OR-2)· Later · Apr 27, 2026
- Rep. Nanette Diaz Barragán (D-CA-44)· Later · Apr 27, 2026
- Rep. Brad Finstad (R-MN-1)· Later · Apr 30, 2026
- Rep. Kelly Morrison (D-MN-3)· Later · Apr 30, 2026
- Rep. Michael Lawler (R-NY-17)· Later · May 21, 2026
- Rep. Eugene Simon Vindman (D-VA-7)· Later · May 21, 2026
- Rep. Sharice Davids (D-KS-3)· Later · May 29, 2026
- Rep. Brian K. Fitzpatrick (R-PA-1)· Later · May 29, 2026
- Policy area
- Health
- Subjects
- Biological and life sciences
- Blood and blood diseases
- Cell biology and embryology
- Health programs administration and funding
- Organ and tissue donation and transplantation
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Referred to Health
Referred to the Subcommittee on Health.
Sources
- Congress.gov action
- House committee actions
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
▸ 6 committee actions · Sep 4, 2025 – Jul 2, 2026
Referred to committee
Referred to the House Committee on Energy and Commerce.
Sources
- Congress.gov action
- House floor actions
Subcommittee markup session held
Subcommittee Consideration and Mark-up Session Held
Sources
- Congress.gov action
- House committee actions
Forwarded by subcommittee
Forwarded by Subcommittee to Full Committee by Voice Vote.
Sources
- Congress.gov action
- House committee actions
Markup session held
Committee Consideration and Mark-up Session Held
Sources
- Congress.gov action
- House committee actions
Ordered reported
Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0.
Sources
- Congress.gov action
- House committee actions
Reported by committee
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-724.
Sources
- Congress.gov action
- House floor actions
- Latest
Passed House
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
The House passed the bill as amended.
Document: Engrossed in House
Sources
- Congress.gov action
- House floor actions
Committees
- HouseEnergy and CommerceReferred Sep 4, 2025 · Markup May 21, 2026 · Reported Jul 2, 2026H. Rept. 119-724
May 13, 2026 · Markup
Floor record
i
Explicit consideration evidence: the measure’s bill-status citation matched a GovInfo title, headline, or first paragraph. Incidental mentions are not listed.
Jul 20, 2026 · House · Considered under suspension of the rulesCongressional Record H4642–H4643
Stem Cell Therapeutic and Research Reauthorization Act of 2025
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House | ||
| Reported in House | ||
| Engrossed in House | ||
| Placed on Calendar Senate |
Titles (2)
Stem Cell Therapeutic and Research Reauthorization Act of 2025
Display title, Short title · Placed on Calendar Senate, Engrossed in House, Reported in House, Introduced in House
To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.
Official title · Engrossed in House, Introduced in House